Figure 4.

Age-adjusted incidence rates of invasive breast cancer by subtype, grade, race/ethnicity for diagnosis year 2011, and areas in the United States with high-quality incidence data*. A) Hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- rates per 100000 women ^Ŧ. B) Triple-negative rates per 100000 women. C) HR+HER2+ rates per 100000 women. D) HR-/HER2+ rates per 100000 women. Error bars represent 95% confidence intervals. *Population-based registries meeting North American Association of Central Cancer Registries quality criteria and high completeness of HR/HER2 data include: Alaska, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawai’i, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming. API = Asian/Pacific Islander; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; NH=Non-Hispanic.